Étienne Myette-Côté1,2, Hannah G Caldwell1,2, Philip N Ainslie1,2, Kieran Clarke3, Jonathan P Little1,2. 1. School of Health and Exercise Sciences, University of British Columbia Okanagan, Kelowna, British Columbia, Canada. 2. Centre for Heart, Lung, and Vascular Health, School of Health and Exercise Sciences, University of British Columbia Okanagan, Kelowna, British Columbia, Canada. 3. Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford, United Kingdom.
Abstract
BACKGROUND: Exogenous ketones make it possible to reach a state of ketosis that may improve metabolic control in humans. OBJECTIVES: The main objective of this study was to determine whether the ingestion of a ketone monoester (KE) drink before a 2-h oral-glucose-tolerance test (OGTT) would lower blood glucose concentrations. Secondary objectives were to determine the impact of KE on nonesterified fatty acid (NEFA) concentration and glucoregulatory hormones. METHODS: We conducted a randomized controlled crossover experiment in 15 individuals with obesity (mean ±SD age: 47 ± 10 y; BMI: 34 ± 5 kg/m2). After an overnight fast, participants consumed a KE drink [(R)-3-hydroxybutyl (R)-3-hydroxybutyrate; 0.45 mL/kg body weight] or taste-matched control drink 30 min before completing a 75-g OGTT. Participants and study personnel performing laboratory analyses were blinded to each condition. RESULTS: The KE increased d-β-hydroxybutyrate to a maximum of ∼3.4 mM (P < 0.001) during the OGTT. Compared with the control drink, KE reduced glucose (-11%, P = 0.002), NEFA (-21%, P = 0.009), and glucagon-like peptide 1 (-31%, P = 0.001) areas under the curve (AUCs), whereas glucagon AUC increased (+11%, P = 0.030). No differences in triglyceride, C-peptide, and insulin AUCs were observed after the KE drink. Mean arterial blood pressure decreased and heart rate increased after the KE drink (both P < 0.01). CONCLUSIONS: A KE drink consumed before an OGTT lowered glucose and NEFA AUCs with no increase in circulating insulin. Our results suggest that a single drink of KE may acutely improve metabolic control in individuals with obesity. Future research is warranted to examine whether KE could be used safely to have longer-term effects on metabolic control. This trial was registered at clinicaltrials.gov as NCT03461068.
RCT Entities:
BACKGROUND: Exogenous ketones make it possible to reach a state of ketosis that may improve metabolic control in humans. OBJECTIVES: The main objective of this study was to determine whether the ingestion of a ketone monoester (KE) drink before a 2-h oral-glucose-tolerance test (OGTT) would lower blood glucose concentrations. Secondary objectives were to determine the impact of KE on nonesterified fatty acid (NEFA) concentration and glucoregulatory hormones. METHODS: We conducted a randomized controlled crossover experiment in 15 individuals with obesity (mean ± SD age: 47 ± 10 y; BMI: 34 ± 5 kg/m2). After an overnight fast, participants consumed a KE drink [(R)-3-hydroxybutyl (R)-3-hydroxybutyrate; 0.45 mL/kg body weight] or taste-matched control drink 30 min before completing a 75-g OGTT. Participants and study personnel performing laboratory analyses were blinded to each condition. RESULTS: The KE increased d-β-hydroxybutyrate to a maximum of ∼3.4 mM (P < 0.001) during the OGTT. Compared with the control drink, KE reduced glucose (-11%, P = 0.002), NEFA (-21%, P = 0.009), and glucagon-like peptide 1 (-31%, P = 0.001) areas under the curve (AUCs), whereas glucagon AUC increased (+11%, P = 0.030). No differences in triglyceride, C-peptide, and insulin AUCs were observed after the KE drink. Mean arterial blood pressure decreased and heart rate increased after the KE drink (both P < 0.01). CONCLUSIONS: A KE drink consumed before an OGTT lowered glucose and NEFA AUCs with no increase in circulating insulin. Our results suggest that a single drink of KE may acutely improve metabolic control in individuals with obesity. Future research is warranted to examine whether KE could be used safely to have longer-term effects on metabolic control. This trial was registered at clinicaltrials.gov as NCT03461068.
Authors: Andrew K P Taggart; Jukka Kero; Xiaodong Gan; Tian-Quan Cai; Kang Cheng; Marc Ippolito; Ning Ren; Rebecca Kaplan; Kenneth Wu; Tsuei-Ju Wu; Lan Jin; Chen Liaw; Ruoping Chen; Jeremy Richman; Daniel Connolly; Stefan Offermanns; Samuel D Wright; M Gerard Waters Journal: J Biol Chem Date: 2005-06-01 Impact factor: 5.157
Authors: Linda E Watson; Liza K Phillips; Tongzhi Wu; Michelle J Bound; Helen L Checklin; Jacqueline Grivell; Karen L Jones; Peter M Clifton; Michael Horowitz; Christopher K Rayner Journal: Diabetes Obes Metab Date: 2019-01-04 Impact factor: 6.577
Authors: Kieran Clarke; Kirill Tchabanenko; Robert Pawlosky; Emma Carter; M Todd King; Kathy Musa-Veloso; Manki Ho; Ashley Roberts; Jeremy Robertson; Theodore B Vanitallie; Richard L Veech Journal: Regul Toxicol Pharmacol Date: 2012-05-03 Impact factor: 3.271
Authors: Shannon L Kesl; Angela M Poff; Nathan P Ward; Tina N Fiorelli; Csilla Ari; Ashley J Van Putten; Jacob W Sherwood; Patrick Arnold; Dominic P D'Agostino Journal: Nutr Metab (Lond) Date: 2016-02-04 Impact factor: 4.169
Authors: Senthil Selvaraj; Ray Hu; Mahesh K Vidula; Supritha Dugyala; Ann Tierney; Bonnie Ky; Kenneth B Margulies; Svati H Shah; Daniel P Kelly; Paco E Bravo Journal: J Am Soc Echocardiogr Date: 2021-11-17 Impact factor: 5.251
Authors: Oliver Chen; Traci M Blonquist; Eunice Mah; Kristen Sanoshy; Dawn Beckman; Kristin M Nieman; Barbara L Winters; Joshua C Anthony; Eric Verdin; John C Newman; Brianna J Stubbs Journal: Nutrients Date: 2021-06-16 Impact factor: 5.717
Authors: Brianna J Stubbs; Andrew P Koutnik; Emily L Goldberg; Vaibhav Upadhyay; Peter J Turnbaugh; Eric Verdin; John C Newman Journal: Med (N Y) Date: 2020-07-15